Literature DB >> 26462056

Impact of brand or generic labeling on medication effectiveness and side effects.

Kate Faasse1, Leslie R Martin2, Andrew Grey1, Greg Gamble1, Keith J Petrie1.   

Abstract

OBJECTIVE: Branding medication with a known pharmaceutical company name or product name bestows on the drug an added assurance of authenticity and effectiveness compared to a generic preparation. This study examined the impact of brand name and generic labeling on medication effectiveness and side effects.
METHOD: 87 undergraduate students with frequent headaches took part in the study. Using a within-subjects counterbalanced design, each participant took tablets labeled either as brand name "Nurofen" or "Generic Ibuprofen" to treat each of 4 headaches. In reality, half of the tablets were placebos, and half were active ibuprofen (400 mg). Participants recorded their headache pain on a verbal descriptor and visual analogue scale prior to taking the tablets, and again 1 hour afterward. Medication side effects were also reported.
RESULTS: Pain reduction following the use of brand name labeled tablets was similar in active ibuprofen or a placebo. However, if the tablets had a generic label, placebo tablets were significantly less effective compared to active ibuprofen. Fewer side effects were attributed to placebo tablets with brand name labeling compared to the same placebo tablets with a generic label.
CONCLUSIONS: Branding of a tablet appears to have conferred a treatment benefit in the absence of an active ingredient, while generic labeled tablets were substantially less effective if they contained no active ingredient. Branding is also associated with reduced attribution of side effects to placebo tablets. Future interventions to improve perceptions of generics may have utility in improving treatment outcomes from generic drugs. (c) 2016 APA, all rights reserved).

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26462056     DOI: 10.1037/hea0000282

Source DB:  PubMed          Journal:  Health Psychol        ISSN: 0278-6133            Impact factor:   4.267


  12 in total

1.  The Placebo Effect in Pain Therapies.

Authors:  Luana Colloca
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-09-14       Impact factor: 13.820

2.  Comparison of Outcomes Following a Switch From a Brand to an Authorized Versus Independent Generic Drug.

Authors:  R A Hansen; J Qian; R L Berg; J G Linneman; E Seoane-Vazquez; S Dutcher; S Raofi; C D Page; P L Peissig
Journal:  Clin Pharmacol Ther       Date:  2017-10-10       Impact factor: 6.875

3.  The influence of message framing on nocebo headaches: Findings from a randomized laboratory design.

Authors:  Suzanne G Helfer; Ben Colagiuri; Kate Faasse; Kelly S Clemens; Fawn Caplandies; Andrew L Geers
Journal:  J Behav Med       Date:  2022-02-14

4.  Analogous comparison of registered brand name drugs of tablets and capsules commercially available in Thailand: A retrospective study.

Authors:  Jintana Napaporn; Pitchaporn Buakaew; Patarawat Suksakornthanawat; Saksit Sripa; Peerawat Jinatongthai; Teeraporn Supapaan
Journal:  PLoS One       Date:  2022-10-19       Impact factor: 3.752

5.  Factors shaping expectations for complete relief from symptoms during rehabilitation for patients with spine pain.

Authors:  Mark D Bishop; Paul Mintken; Joel E Bialosky; Joshua A Cleland
Journal:  Physiother Theory Pract       Date:  2018-02-16       Impact factor: 2.279

Review 6.  The placebo and nocebo effects in functional urology.

Authors:  Hadi Mostafaei; Sandra Jilch; Greta Lisa Carlin; Keiichiro Mori; Fahad Quhal; Benjamin Pradere; Ekaterina Laukhtina; Victor M Schuettfort; Abdulmajeed Aydh; Reza Sari Motlagh; Claus G Roehrborn; Shahrokh F Shariat; Sakineh Hajebrahimi
Journal:  Nat Rev Urol       Date:  2021-12-23       Impact factor: 14.432

7.  Comparison of the efficacy and safety of CELBESTA® versus CELEBREX® in patients with rheumatoid arthritis: a 6-week, multicenter, double-blind, double-dummy, active-controlled, randomized, parallel-group, non-inferiority phase 4 clinical trial.

Authors:  Hyun-Sook Kim; Won-Ho Choi; Bo Young Kim; Sung Soo Kim; Sang-Il Lee; Sang-Hyon Kim; Sung Jae Choi; Geun-Tae Kim; Jin-Wuk Hur; Myeung-Su Lee; Yun Sung Kim; Seung-Jae Hong
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

Review 8.  Putting the 'Art' Into the 'Art of Medicine': The Under-Explored Role of Artifacts in Placebo Studies.

Authors:  Michael H Bernstein; Cosima Locher; Tobias Kube; Sarah Buergler; Sif Stewart-Ferrer; Charlotte Blease
Journal:  Front Psychol       Date:  2020-07-22

9.  What is associated with increased side effects and lower perceived efficacy following switching to a generic medicine? A New Zealand cross-sectional patient survey.

Authors:  Kate MacKrill; Keith J Petrie
Journal:  BMJ Open       Date:  2018-10-18       Impact factor: 2.692

10.  A multivariate investigation into the relationship between pharmaceutical characteristics and patient preferences of bioequivalent ibuprofen tablets.

Authors:  Tatiana R Alonso; Adrianna Gagol; Maximilian Scherer; Antonio Matji; Santiago Torrado-Santiago; Dolores R Serrano; Alfredo Garcia-Arieta; Juan J Torrado
Journal:  Patient Prefer Adherence       Date:  2018-09-26       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.